Portolan Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Portolan Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-52,389	Closed	-$2.62M	–	149
2016 Q3	$2.62M	Buy	+52,389	New	+$2.17M	0.36%	82
2016 Q2	–	Sell	-28,858	Closed	-$1.9M	–	127
2016 Q1	$1.9M	Buy	+28,858	New	+$1.51M	0.25%	100
2015 Q4	–	Sell	-56,502	Closed	-$3.78M	–	145
2015 Q3	$3.78M	Sell	56,502 -27,930	-33%	-$2.28M	0.5%	81
2015 Q2	$8.21M	Buy	84,432 +15,846	+23%	+$1.51M	1.15%	27
2015 Q1	$6.41M	Sell	68,586 -8,600	-11%	-$732K	1.18%	25
2014 Q4	$6.86M	Buy	77,186 +23,426	+44%	+$1.71M	1.37%	23
2014 Q3	$3.71M	Buy	+53,760	New	+$2.87M	0.84%	52

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Portolan Capital Management's MACK Position: Q4 2016 in Review

Portolan Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 52,389 shares — an estimated $2.62M sold.

Portolan Capital Management first reported a position in MACK in Q3 2014 and held it in 7 quarters. The position peaked at $8.21M in Q2 2015. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

Portolan Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Portolan Capital Management sold 52,389 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $2.62M.
Portolan Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 7 quarters.
Portolan Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $8.21M in Q2 2015.
136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on Portolan Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.